This article is more than 5 years old. Information may no longer be current.

VIDEO: Lutathera 'an exciting new option for therapy' in midgut neuroendocrine tumors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Vincent J. Picozzi, MD, a medical oncologist from Virginia Mason Medical Center in Seattle, reacts to results from the phase 3 NETTER-1 trial presented at the Gastrointestinal Cancers Symposium.

One abstract “of particular interest and … import to clinicians … was presented by [Jonathan R. Strosberg, MD,] from the Moffitt Cancer Center in Tampa, Fla., in which there was a comparison … of a radioactive form of octreotide [and] the standard form of octreotide used to treat patients with midgut neuroendocrine cancers,” Picozzi said. “In this rather large trial … there was a striking difference in disease control and time to progression using the radioactive compound as opposed to the standard compound.”

Disclosure: Picozzi reports stock and ownership interests in AbbVie, Amgen and Johnson & Johnson; honoraria from Celgene; consulting or advisory roles for Halozyme and Taiho Pharmaceutical; and research funding from Aduro Biotech, Clovis Oncology, FibroGen, Immunomedics, Incyte, OncoMed and Theranostics Health.